



FOR IMMEDIATE RELEASE

Contact:

Lisa Romero
Communications & Development Manager
520-547-3440
lromero@c-path.org
www.c-path.org

CRITICAL PATH INSTITUTE CONTINUES GROWTH WITH KEY ADDITION Martha Brumfield, PhD, Hired as Director, International Programs



Tucson, Arizona, December 9, 2010 – Martha Brumfield, PhD, has joined Critical Path Institute (C-Path) as Director of International Programs. Dr. Brumfield was most recently Senior Vice President, Worldwide Regulatory Affairs and Quality Assurance at Pfizer, Inc. Dr. Brumfield led a global team that supported lifecycle pharmaceutical research, development and commercialization through creation and implementation of regulatory strategies and quality assurance oversight. She also played a key role in managing the broader company relationships with global regulators, trade associations, academics and others on regulatory policy issues. Dr. Brumfield has been active in several external organizations including PhRMA, CMR, and APEC LSIF, and has worked extensively with the PhRMA Simultaneous Global Development program.

During 20 years at Pfizer, Dr. Brumfield held a variety of leadership positions in which she led regulatory teams responsible for the U.S., Europe and Emerging Markets. Dr. Brumfield also served as the company's head of drug safety surveillance and reporting, and managed global adverse event reporting requirements and the integration of Pharmacia's related safety operations. She earned a MS and BS in Chemistry from Virginia Commonwealth University, a PhD in Organic Chemistry from the University of Maryland, and served as a post-doctoral fellow at The Rockefeller University.

"We are extremely fortunate that Dr. Brumfield will now lend her expertise in global pharmaceutical development to lead our international regulatory and collaborative programs," said Dr. Ray Woosley, President and CEO of C-Path. "She will represent our consortia in their work with regulatory agencies around the world, especially the Critical Path for TB Drug Regimens, a partnership between C-Path, the Bill and Melinda Gates Foundation, and the Global Alliance for TB Drug Development (TB Alliance). She will also represent C-Path in our collaborations with the Innovative Medicines Initiative, C-Path's companion organization in the European Union working to improve drug development."

According to Dr. Brumfield, "I am honored to represent C-Path on the international stage. Drug development is now global, and accordingly, C-Path's programs must be coordinated with companies, non-profit organizations, and regulatory agencies around the world."

About Critical Path Institute (C-Path): An independent, non-profit organization established in 2005, C-Path is committed to transformational improvement of the drug development process. An international leader in forming collaborations around this mission, C-Path has brought recognition to Arizona through innovative, global programs and partnerships which currently include over 750 scientists from government regulatory agencies, academia, patient advocacy organizations, and thirty major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit www.c-path.org.

###